Elevance Health, Inc. $ELV is Baupost Group LLC MA’s 4th Largest Position

Baupost Group LLC MA reduced its stake in Elevance Health, Inc. (NYSE:ELV) by 3.8% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 1,269,302 shares of the company’s stock after selling 49,698 shares during the quarter. Elevance Health comprises about 8.4% of Baupost Group LLC MA’s portfolio, making the stock its 4th largest holding. Baupost Group LLC MA’s holdings in Elevance Health were worth $444,954,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also recently modified their holdings of the stock. Vanguard Group Inc. raised its position in shares of Elevance Health by 0.6% in the 3rd quarter. Vanguard Group Inc. now owns 22,998,645 shares of the company’s stock valued at $7,431,322,000 after purchasing an additional 141,747 shares during the last quarter. Wellington Management Group LLP raised its position in shares of Elevance Health by 4.8% in the 3rd quarter. Wellington Management Group LLP now owns 6,621,297 shares of the company’s stock valued at $2,139,473,000 after purchasing an additional 303,099 shares during the last quarter. Artisan Partners Limited Partnership increased its holdings in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after buying an additional 901,626 shares during the period. First Eagle Investment Management LLC raised its position in Elevance Health by 0.6% during the 4th quarter. First Eagle Investment Management LLC now owns 4,022,874 shares of the company’s stock worth $1,410,219,000 after buying an additional 24,271 shares during the last quarter. Finally, Norges Bank purchased a new position in Elevance Health during the 4th quarter worth approximately $1,058,165,000. 89.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts have issued reports on ELV shares. Sanford C. Bernstein raised their price target on shares of Elevance Health from $384.00 to $424.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. Barclays raised their price target on shares of Elevance Health from $408.00 to $480.00 and gave the stock an “overweight” rating in a research report on Tuesday, May 26th. Mizuho raised their price target on shares of Elevance Health from $435.00 to $465.00 and gave the stock an “outperform” rating in a research report on Monday, June 8th. Deutsche Bank Aktiengesellschaft raised shares of Elevance Health from a “hold” rating to a “buy” rating and raised their price target for the stock from $363.00 to $498.00 in a research report on Wednesday, May 20th. Finally, Bank of America raised their price target on shares of Elevance Health from $435.00 to $460.00 and gave the stock a “buy” rating in a research report on Thursday, June 4th. Fourteen analysts have rated the stock with a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Elevance Health presently has an average rating of “Moderate Buy” and an average target price of $416.11.

Insider Activity at Elevance Health

In other news, Director Robert L. Dixon, Jr. sold 151 shares of the firm’s stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $401.77, for a total transaction of $60,667.27. Following the sale, the director owned 10,734 shares of the company’s stock, valued at $4,312,599.18. This trade represents a 1.39% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.34% of the stock is owned by insiders.

Elevance Health Price Performance

Shares of NYSE ELV opened at $403.74 on Friday. The stock has a market capitalization of $87.68 billion, a price-to-earnings ratio of 17.17, a PEG ratio of 2.29 and a beta of 0.67. Elevance Health, Inc. has a 12 month low of $273.71 and a 12 month high of $426.98. The firm’s 50 day simple moving average is $366.62 and its 200-day simple moving average is $344.86. The company has a debt-to-equity ratio of 0.70, a current ratio of 1.48 and a quick ratio of 1.48.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Wednesday, April 22nd. The company reported $12.58 EPS for the quarter, topping analysts’ consensus estimates of $10.74 by $1.84. The business had revenue of $49.49 billion for the quarter, compared to analysts’ expectations of $48.21 billion. Elevance Health had a net margin of 2.62% and a return on equity of 15.58%. The business’s revenue was up 1.5% on a year-over-year basis. During the same quarter last year, the company earned $11.97 EPS. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Analysts expect that Elevance Health, Inc. will post 26.93 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, June 25th. Stockholders of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. The ex-dividend date of this dividend is Wednesday, June 10th. This represents a $6.88 dividend on an annualized basis and a dividend yield of 1.7%. Elevance Health’s dividend payout ratio (DPR) is presently 29.26%.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.